NovaBay Trading Resumes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy NBY?
NovaBay trading resumes
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBY
About NBY
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
- Earnings Performance: Netflix's Q4 earnings report revealed revenue of $12.16 billion, exceeding expectations, yet its Q1 guidance of $12.16 billion fell short of the $12.19 billion consensus, causing shares to drop 5.7% to $82.32 in pre-market trading.
- Earnings Per Share Outlook: The company anticipates Q1 earnings per share of 76 cents, below the consensus estimate of 81 cents, indicating pressure on user growth and profitability, which may undermine investor confidence.
- Other Stock Movements: Erasca Inc announced a proposed $150 million public offering, leading to a 6.2% decline in its pre-market share price to $9.20, highlighting market sensitivity to new stock issuances.
- Market Reaction: Kraft Heinz Co shares fell 5.3% to $22.51 as Berkshire Hathaway filed to sell up to 325 million shares, intensifying market concerns regarding its future performance.
See More
D.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates
- Earnings Highlight: D.R. Horton reported a net income of $594.8 million for Q1 2026, translating to $2.03 per diluted share, surpassing the analyst estimate of $1.95, despite a revenue decline to $6.887 billion, showcasing the company's resilience amid market fluctuations.
- Sales Performance: While total revenue decreased from $7.613 billion year-over-year, sales exceeded expectations at $6.603 billion, indicating the company's strong sales capability in a competitive real estate market.
- Market Reaction: Amidst a broader market downturn, D.R. Horton's stock price remained relatively stable, reflecting investor confidence in its financial health, which may lay the groundwork for future growth.
- Industry Trends: Given the volatility in the real estate market, D.R. Horton's robust earnings report could attract more investor attention, particularly as economic uncertainties rise, positioning the company as a potential bellwether in the industry.
See More
NovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas
- Stock Price Plunge: NovaBay Pharmaceuticals saw its stock price drop approximately 54% on Tuesday following the announcement of a $100M stock sale agreement with Virtu Americas, indicating market concerns regarding this financing method.
- Sales Agreement Details: Under the agreement signed on January 20, NovaBay can sell its common stock at a par value of $0.01 per share, with Virtu acting as the sales agent, allowing for flexible fundraising opportunities for the company.
- Commission Structure: Virtu is entitled to a commission of up to 2.0% on any sales, meaning if $100M worth of stock is sold, Virtu could earn up to $2 million, potentially impacting NovaBay's net proceeds from the sales.
- Market Reaction: While this agreement provides funding support for NovaBay, heightened market concerns about the company's future direction have led analysts to maintain a “Hold” rating, reflecting caution regarding potential M&A risks.
See More
J.B. Hunt Reports Q4 Revenue Slightly Below Estimates, Shares Drop 4.2%
- Financial Performance: J.B. Hunt Transport Services Inc. reported fourth-quarter revenue of $3.097 billion, slightly below the market expectation of $3.099 billion, indicating pressure in the competitive transport market.
- Earnings Beat: Despite the revenue miss, J.B. Hunt's earnings per share came in at $1.90, exceeding analyst expectations of $1.77, suggesting effective cost control measures by the company.
- Stock Price Movement: Following the earnings report, J.B. Hunt's shares fell 4.2% in pre-market trading to $197.86, reflecting investor disappointment over the revenue shortfall.
- Market Dynamics: Other companies like TryHard Holdings and High Roller Technologies also experienced significant pre-market fluctuations, with TryHard's shares dropping 16.4% due to a cooperation announcement, while High Roller saw a 12.9% decline after signing a letter of intent.
See More
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
See More
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
See More
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
- Earnings Performance: Netflix's Q4 earnings report revealed revenue of $12.16 billion, exceeding expectations, yet its Q1 guidance of $12.16 billion fell short of the $12.19 billion consensus, causing shares to drop 5.7% to $82.32 in pre-market trading.
- Earnings Per Share Outlook: The company anticipates Q1 earnings per share of 76 cents, below the consensus estimate of 81 cents, indicating pressure on user growth and profitability, which may undermine investor confidence.
- Other Stock Movements: Erasca Inc announced a proposed $150 million public offering, leading to a 6.2% decline in its pre-market share price to $9.20, highlighting market sensitivity to new stock issuances.
- Market Reaction: Kraft Heinz Co shares fell 5.3% to $22.51 as Berkshire Hathaway filed to sell up to 325 million shares, intensifying market concerns regarding its future performance.
See More
D.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates
- Earnings Highlight: D.R. Horton reported a net income of $594.8 million for Q1 2026, translating to $2.03 per diluted share, surpassing the analyst estimate of $1.95, despite a revenue decline to $6.887 billion, showcasing the company's resilience amid market fluctuations.
- Sales Performance: While total revenue decreased from $7.613 billion year-over-year, sales exceeded expectations at $6.603 billion, indicating the company's strong sales capability in a competitive real estate market.
- Market Reaction: Amidst a broader market downturn, D.R. Horton's stock price remained relatively stable, reflecting investor confidence in its financial health, which may lay the groundwork for future growth.
- Industry Trends: Given the volatility in the real estate market, D.R. Horton's robust earnings report could attract more investor attention, particularly as economic uncertainties rise, positioning the company as a potential bellwether in the industry.
See More
NovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas
- Stock Price Plunge: NovaBay Pharmaceuticals saw its stock price drop approximately 54% on Tuesday following the announcement of a $100M stock sale agreement with Virtu Americas, indicating market concerns regarding this financing method.
- Sales Agreement Details: Under the agreement signed on January 20, NovaBay can sell its common stock at a par value of $0.01 per share, with Virtu acting as the sales agent, allowing for flexible fundraising opportunities for the company.
- Commission Structure: Virtu is entitled to a commission of up to 2.0% on any sales, meaning if $100M worth of stock is sold, Virtu could earn up to $2 million, potentially impacting NovaBay's net proceeds from the sales.
- Market Reaction: While this agreement provides funding support for NovaBay, heightened market concerns about the company's future direction have led analysts to maintain a “Hold” rating, reflecting caution regarding potential M&A risks.
See More
J.B. Hunt Reports Q4 Revenue Slightly Below Estimates, Shares Drop 4.2%
- Financial Performance: J.B. Hunt Transport Services Inc. reported fourth-quarter revenue of $3.097 billion, slightly below the market expectation of $3.099 billion, indicating pressure in the competitive transport market.
- Earnings Beat: Despite the revenue miss, J.B. Hunt's earnings per share came in at $1.90, exceeding analyst expectations of $1.77, suggesting effective cost control measures by the company.
- Stock Price Movement: Following the earnings report, J.B. Hunt's shares fell 4.2% in pre-market trading to $197.86, reflecting investor disappointment over the revenue shortfall.
- Market Dynamics: Other companies like TryHard Holdings and High Roller Technologies also experienced significant pre-market fluctuations, with TryHard's shares dropping 16.4% due to a cooperation announcement, while High Roller saw a 12.9% decline after signing a letter of intent.
See More
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
See More
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
See More
